As prostate cancer progresses, androgen metabolism changes ... With the development of the newer agents, abiraterone acetate and enzalutamide, efforts have been made to better define the basis ...

Abiraterone acetate plus prednisone and enzalutamide ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

Two agents (cabazitaxel and abiraterone) are already accessible ... A future in which metastatic castrate-resistant prostate cancer can be managed as a 'chronic disease' looks tantalizingly ...

Prostate cancer is the most common cancer among men ... a PARP inhibitor, with abiraterone acetate, given with prednisone, versus abiraterone acetate and prednisone for the treatment of ...

NICE is unable to make a recommendation about the use in the NHS of niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is ...

slowed the growth of prostate cancer cells, including in cancer cells that are resistant to the hormone therapy enzalutamide. Although hormone therapies like enzalutamide and abiraterone transform the ...

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...

which evaluated Truqap combined with abiraterone and androgen deprivation therapy (ADT) for prostate cancer. Truqap showed improvement in radiographic progression-free survival (rPFS) in the trial ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

he also runs a separate group focused on improving prostate cancer care that have led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide and ...